NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free DCTH Stock Alerts $5.71 -0.06 (-1.04%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$5.66▼$5.8950-Day Range$3.72▼$5.6052-Week Range$2.25▼$7.99Volume137,412 shsAverage Volume221,169 shsMarket Capitalization$158.62 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.0% Upside$18.50 Price TargetShort InterestHealthy2.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$100,001 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.45) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector289th out of 903 stocksSurgical & Medical Instruments Industry38th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 1 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.96% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently decreased by 12.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Delcath Systems this week, compared to 1 article on an average week.Search Interest7 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows4 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.45) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 7.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesMay 7, 2024 | prnewswire.comDelcath Systems to Host First Quarter 2024 Earnings CallMay 6, 2024 | prnewswire.comPublication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KITMay 7, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 3, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finance.yahoo.comDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)March 27, 2024 | finance.yahoo.comDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call TranscriptMay 7, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 26, 2024 | finance.yahoo.comDelcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic AdvancementsMarch 26, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 26, 2024 | msn.comDelcath Systems GAAP EPS of -$0.48, revenue of $0.54MMarch 26, 2024 | prnewswire.comDelcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 25, 2024 | msn.comDelcath Systems Q4 2023 Earnings PreviewMarch 23, 2024 | finance.yahoo.comInsiders of Delcath Systems Getting Good Value On Their US$736.5k InvestmentMarch 20, 2024 | prnewswire.comDelcath Systems Closes $7 Million Private PlacementMarch 19, 2024 | prnewswire.comDelcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update CallMarch 19, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 18, 2024 | markets.businessinsider.comDelcath Systems Appoints Martha Rook As COOMarch 18, 2024 | prnewswire.comDelcath Systems Appoints Martha S. Rook as Chief Operating OfficerMarch 17, 2024 | investing.comDelcath Systems secures $7 million in private placementMarch 16, 2024 | finance.yahoo.comDCTH Apr 2024 7.500 callMarch 15, 2024 | markets.businessinsider.comDelcath Announces $7 Mln Private PlacementMarch 15, 2024 | prnewswire.comDelcath Systems Announces $7 Million Private PlacementMarch 8, 2024 | prnewswire.comDelcath Systems to Participate in Upcoming Investor ConferencesFebruary 22, 2024 | stockhouse.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)February 22, 2024 | finance.yahoo.comDelcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)See More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/07/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees76Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$21.00 Low Stock Price Target$13.00 Potential Upside/Downside+221.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,680,000.00 Net Margins-2,308.86% Pretax Margin-2,308.86% Return on Equity-563.60% Return on Assets-111.13% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.06 Sales & Book Value Annual Sales$2.07 million Price / Sales77.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book8.00Miscellaneous Outstanding Shares27,780,000Free Float22,800,000Market Cap$160.01 million OptionableOptionable Beta0.55 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $727.97kMs. Sandra Pennell (Age 44)Senior VP of Finance and Principal Financial & Accounting Officer Dr. Martha S. Rook Ph.D. (Age 54)Chief Operating Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Johnny John M.D. (Age 59)Senior Vice President of Clinical Operations & Medical Affairs Comp: $472.16kDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsClearPoint NeuroNASDAQ:CLPTQuipt Home MedicalNASDAQ:QIPTTELA BioNASDAQ:TELAOrchestra BioMedNASDAQ:OBIONeuroneticsNASDAQ:STIMView All CompetitorsInsiders & InstitutionsVivo Capital LLCBought 811,555 shares on 4/22/2024Ownership: 6.552%Gil AharonBought 26,882 shares on 3/19/2024Total: $100,001.04 ($3.72/share)ADAR1 Capital Management LLCBought 231,302 shares on 2/14/2024Ownership: 1.049%AIGH Capital Management LLCBought 1,182,198 shares on 2/12/2024Ownership: 5.361%Worth Venture Partners LLCBought 294,248 shares on 2/9/2024Ownership: 1.334%View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions Should I buy or sell Delcath Systems stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks. What is Delcath Systems' stock price target for 2024? 4 Wall Street analysts have issued 12-month target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they anticipate the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 224.0% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts. How have DCTH shares performed in 2024? Delcath Systems' stock was trading at $4.16 on January 1st, 2024. Since then, DCTH shares have increased by 37.3% and is now trading at $5.71. View the best growth stocks for 2024 here. Are investors shorting Delcath Systems? Delcath Systems saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 821,200 shares, a decline of 12.3% from the March 31st total of 936,300 shares. Based on an average daily trading volume, of 209,800 shares, the short-interest ratio is presently 3.9 days. View Delcath Systems' Short Interest. When is Delcath Systems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DCTH earnings forecast. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.19. The company earned $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same quarter in the previous year, the firm earned ($0.86) earnings per share. When did Delcath Systems' stock split? Delcath Systems shares reverse split before market open on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (6.55%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBiden replacement revealed?Paradigm PressThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
